Cancer stem cells and metastasis

Seminars in Cancer Biology

Volumn 22, Issue 3, 2012, Pages 187-193

  Sampieri, Katia ^a   Fodde, Riccardo ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

Cancer stem cells; Cancer therapy; Metastasis; Tumour dormancy

Indexed keywords

CD133 ANTIGEN; CD24 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYTOKERATIN 19; DIPEPTIDYL PEPTIDASE IV; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; MUCIN 1; NOTCH RECEPTOR; SONIC HEDGEHOG PROTEIN;

APC GENE; CANCER GROWTH; CANCER INVASION; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL LINEAGE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CXCR1 GENE; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE EXPRESSION; GENE FUNCTION; HUMAN; IL8 GENE; IL8RA GENE; METASTASIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMANS; MICE; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC STEM CELLS; PYRANS;

EID: 84861194295     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2012.03.002     Document Type: Review

References (108)

1. Li L., Clevers H. Coexistence of quiescent and active adult stem cells in mammals. Science 2010, 327:542-545.
2. Barker N., Ridgway R.A., van Es J.H., van de Wetering M., Begthel H., van den Born M., et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009, 457:608-611.
3. Zhu L., Gibson P., Currle D.S., Tong Y., Richardson R.J., Bayazitov I.T., et al. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009, 457:603-607.
4. Cozzio A., Passegue E., Ayton P.M., Karsunky H., Cleary M.L., Weissman I.L. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003, 17:3029-3035.
5. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008, 8:755-768.
6. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
7. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100:3983-3988.
8. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
9. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
10. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
11. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., et al. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006, 66:9339-9344.
12. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
13. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008, 14:818-829.
14. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
15. Le N.H., Franken P., Fodde R. Tumour-stroma interactions in colorectal cancer: converging on beta-catenin activation and cancer stemness. Br J Cancer 2008, 98:1886-1893.
16. Brabletz T., Jung A., Reu S., Porzner M., Hlubek F., Kunz-Schughart L.A., et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A 2001, 98:10356-10361.
17. Brabletz T., Jung A., Spaderna S., Hlubek F., Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 2005, 5:744-749.
18. Fodde R., Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 2007, 19:150-158.
19. Pantel K., Brakenhoff R.H. Dissecting the metastatic cascade. Nat Rev Cancer 2004, 4:448-456.
20. Pantel K., Brakenhoff R.H., Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008, 8:329-340.
21. Pantel K., Alix-Panabieres C., Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 2009, 6:339-351.
22. Braun S., Vogl F.D., Naume B., Janni W., Osborne M.P., Coombes R.C., et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005, 353:793-802.
23. Becker S., Becker-Pergola G., Wallwiener D., Solomayer E.F., Fehm T. Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy. Breast Cancer Res Treat 2006, 97:91-96.
24. Becker S., Solomayer E., Becker-Pergola G., Wallwiener D., Fehm T. Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients. Breast Cancer Res Treat 2007, 106:239-243.
25. Muller V., Stahmann N., Riethdorf S., Rau T., Zabel T., Goetz A., et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 2005, 11:3678-3685.
26. Alix-Panabieres C., Vendrell J.P., Pelle O., Rebillard X., Riethdorf S., Muller V., et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 2007, 53:537-539.
27. Balic M., Lin H., Young L., Hawes D., Giuliano A., McNamara G., et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006, 12:5615-5621.
28. Gassmann P., Haier J., Schluter K., Domikowsky B., Wendel C., Wiesner U., et al. CXCR4 regulates the early extravasation of metastatic tumor cells in vivo. Neoplasia 2009, 11:651-661.
29. Huang C.Y., Lee C.Y., Chen M.Y., Yang W.H., Chen Y.H., Chang C.H., et al. Stromal cell-derived factor-1/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1/2, ERK and NF-kappaB-dependent pathways. J Cell Physiol 2009, 221:204-212.
30. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
31. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
32. Dalerba P., Dylla S.J., Park I.K., Liu R., Wang X., Cho R.W., et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007, 104:10158-10163.
33. Vermeulen L., De Sousa E.M.F., van der Heijden M., Cameron K., de Jong J.H., Borovski T., et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010, 12:468-476.
34. Dieter S.M., Ball C.R., Hoffmann C.M., Nowrouzi A., Herbst F., Zavidij O., et al. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 2011, 9:357-365.
35. + cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 2010, 6:603-615.
36. Merlos-Suarez A., Barriga F.M., Jung P., Iglesias M., Cespedes M.V., Rossell D., et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011, 8:511-524.
37. de Sousa E.M.F., Colak S., Buikhuisen J., Koster J., Cameron K., de Jong J.H., et al. Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell 2011, 9:476-485.
38. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
39. Chute J.P., Muramoto G.G., Whitesides J., Colvin M., Safi R., Chao N.J., et al. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci U S A 2006, 103:11707-11712.
40. Charafe-Jauffret E., Ginestier C., Iovino F., Wicinski J., Cervera N., Finetti P., et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009, 69:1302-1313.
41. Croker A.K., Goodale D., Chu J., Postenka C., Hedley B.D., Hess D.A., et al. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 2009, 13:2236-2252.
42. Jiang F., Qiu Q., Khanna A., Todd N.W., Deepak J., Xing L., et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009, 7:330-338.
43. Chen Y.C., Chen Y.W., Hsu H.S., Tseng L.M., Huang P.I., Lu K.H., et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun 2009, 385:307-313.
44. Sun S., Wang Z. ALDH high adenoid cystic carcinoma cells display cancer stem cell properties and are responsible for mediating metastasis. Biochem Biophys Res Commun 2010, 396:843-848.
45. Shipitsin M., Polyak K. The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest 2008, 88:459-463.
46. Huff C.A., Matsui W., Smith B.D., Jones R.J. The paradox of response and survival in cancer therapeutics. Blood 2006, 107:431-434.
47. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
48. Creighton C.J., Li X., Landis M., Dixon J.M., Neumeister V.M., Sjolund A., et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 2009, 106:13820-13825.
49. Li H.Z., Yi T.B., Wu Z.Y. Suspension culture combined with chemotherapeutic agents for sorting of breast cancer stem cells. BMC Cancer 2008, 8:135.
50. Phillips T.M., McBride W.H., Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006, 98:1777-1785.
51. Roth S., Fodde R. Quiescent stem cells in intestinal homeostasis and cancer. Cell Commun Adhes 2011, 18:33-44.
52. Aguirre-Ghiso J.A. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007, 7:834-846.
53. Muller V., Alix-Panabieres C., Pantel K. Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies. Eur J Cancer 2010, 46:1189-1197.
54. Hanrahan E.O., Gonzalez-Angulo A.M., Giordano S.H., Rouzier R., Broglio K.R., Hortobagyi G.N., et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 2007, 25:4952-4960.
55. Saphner T., Tormey D.C., Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996, 14:2738-2746.
56. Sargent D.J., Patiyil S., Yothers G., Haller D.G., Gray R., Benedetti J., et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 2007, 25:4569-4574.
57. Roesch A., Fukunaga-Kalabis M., Schmidt E.C., Zabierowski S.E., Brafford P.A., Vultur A., et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010, 141:583-594.
58. Saito Y., Uchida N., Tanaka S., Suzuki N., Tomizawa-Murasawa M., Sone A., et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol 2010, 28:275-280.
59. Pece S., Tosoni D., Confalonieri S., Mazzarol G., Vecchi M., Ronzoni S., et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010, 140:62-73.
60. Gao M.Q., Choi Y.P., Kang S., Youn J.H., Cho N.H. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010, 29:2672-2680.
61. Kusumbe A.P., Bapat S.A. Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res 2009, 69:9245-9253.
62. Dembinski J.L., Krauss S. Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. Clin Exp Metastasis 2009, 26:611-623.
63. Haraguchi N., Ishii H., Mimori K., Tanaka F., Ohkuma M., Kim H.M., et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 2010, 120:3326-3339.
64. Knutsen T., Mickley L.A., Ried T., Green E.D., du Manoir S., Schrock E., et al. Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL. Genes Chromosomes Cancer 1998, 23:44-54.
65. Mickley L.A., Spengler B.A., Knutsen T.A., Biedler J.L., Fojo T. Gene rearrangement: a novel mechanism for MDR-1 gene activation. J Clin Invest 1997, 99:1947-1957.
66. Diehn M., Cho R.W., Lobo N.A., Kalisky T., Dorie M.J., Kulp A.N., et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783.
67. Wang S., Yang D., Lippman M.E. Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol 2003, 30:133-142.
68. Stassi G., Todaro M., Zerilli M., Ricci-Vitiani L., Di Liberto D., Patti M., et al. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res 2003, 63:6784-6790.
69. Todaro M., Alea M.P., Di Stefano A.B., Cammareri P., Vermeulen L., Iovino F., et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007, 1:389-402.
70. Rich J.N., Bao S. Chemotherapy and cancer stem cells. Cell Stem Cell 2007, 1:353-355.
71. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
72. Jones R.J. Cancer stem cells-clinical relevance. J Mol Med (Berl) 2009, 87:1105-1110.
73. Fortini M.E. Notch signaling: the core pathway and its posttranslational regulation. Dev Cell 2009, 16:633-647.
74. Dontu G., Jackson K.W., McNicholas E., Kawamura M.J., Abdallah W.M., Wicha M.S. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 2004, 6:R605-R615.
75. Harrison H., Farnie G., Howell S.J., Rock R.E., Stylianou S., Brennan K.R., et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 2010, 70:709-718.
76. Hoey T., Yen W.C., Axelrod F., Basi J., Donigian L., Dylla S., et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009, 5:168-177.
77. Li K., Li Y., Wu W., Gordon W.R., Chang D.W., Lu M., et al. Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3. J Biol Chem 2008, 283:8046-8054.
78. Tammam J., Ware C., Efferson C., O'Neil J., Rao S., Qu X., et al. Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia. Br J Pharmacol 2009, 158:1183-1195.
79. McGowan P.M., Simedrea C., Ribot E.J., Foster P.J., Palmieri D., Steeg P.S., et al. Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. Mol Cancer Res 2011, 9:834-844.
80. Dierks C., Beigi R., Guo G.R., Zirlik K., Stegert M.R., Manley P., et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008, 14:238-249.
81. Hofmann I., Stover E.H., Cullen D.E., Mao J., Morgan K.J., Lee B.H., et al. Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell 2009, 4:559-567.
82. Merchant A.A., Matsui W. Targeting Hedgehog - a cancer stem cell pathway. Clin Cancer Res 2010, 16:3130-3140.
83. Watkins D.N., Berman D.M., Burkholder S.G., Wang B., Beachy P.A., Baylin S.B. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 2003, 422:313-317.
84. Xie J., Murone M., Luoh S.M., Ryan A., Gu Q., Zhang C., et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998, 391:90-92.
85. Jiang J., Hui C.C. Hedgehog signaling in development and cancer. Dev Cell 2008, 15:801-812.
86. Feldmann G., Fendrich V., McGovern K., Bedja D., Bisht S., Alvarez H., et al. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther 2008, 7:2725-2735.
87. Nusse R., Fuerer C., Ching W., Harnish K., Logan C., Zeng A., et al. Wnt signaling and stem cell control. Cold Spring Harb Symp Quant Biol 2008, 73:59-66.
88. Malanchi I., Peinado H., Kassen D., Hussenet T., Metzger D., Chambon P., et al. Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 2008, 452:650-653.
89. Reya T., Clevers H. Wnt signalling in stem cells and cancer. Nature 2005, 434:843-850.
90. Watt F.M., Collins C.A. Role of beta-catenin in epidermal stem cell expansion, lineage selection, and cancer. Cold Spring Harb Symp Quant Biol 2008, 73:503-512.
91. Zeng Y.A., Nusse R. Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture. Cell Stem Cell 2010, 6:568-577.
92. Fodde R., Smits R., Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 2001, 1:55-67.
93. Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-1790.
94. Chen B., Dodge M.E., Tang W., Lu J., Ma Z., Fan C.W., et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009, 5:100-107.
95. Fujii N., You L., Xu Z., Uematsu K., Shan J., He B., et al. An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res 2007, 67:573-579.
96. Shan J., Shi D.L., Wang J., Zheng J. Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry 2005, 44:15495-15503.
97. Emami K.H., Nguyen C., Ma H., Kim D.H., Jeong K.W., Eguchi M., et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci U S A 2004, 101:12682-12687.
98. He B., Reguart N., You L., Mazieres J., Xu Z., Lee A.Y., et al. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 2005, 24:3054-3058.
99. You L., He B., Xu Z., Uematsu K., Mazieres J., Fujii N., et al. An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res 2004, 64:5385-5389.
100. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
101. Lu D., Choi M.Y., Yu J., Castro J.E., Kipps T.J., Carson D.A. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A 2011, 108:13253-13257.
102. Tang Q.L., Zhao Z.Q., Li J.C., Liang Y., Yin J.Q., Zou C.Y., et al. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. Cancer Lett 2011, 311:113-121.
103. Ginestier C., Liu S., Diebel M.E., Korkaya H., Luo M., Brown M., et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 2010, 120:485-497.
104. Elwood P.C., Gallagher A.M., Duthie G.G., Mur L.A., Morgan G. Aspirin, salicylates, and cancer. Lancet 2009, 373:1301-1309.
105. Cianferoni A., Schroeder J.T., Kim J., Schmidt J.W., Lichtenstein L.M., Georas S.N., et al. Selective inhibition of interleukin-4 gene expression in human T cells by aspirin. Blood 2001, 97:1742-1749.
106. Chan A.T., Ogino S., Fuchs C.S. Aspirin use and survival after diagnosis of colorectal cancer. Jama 2009, 302:649-658.
107. Neugut A.I. Aspirin as adjuvant therapy for colorectal cancer: a promising new twist for an old drug. Jama 2009, 302:688-689.
108. Buijs J.T., van der Horst G., van den Hoogen C., Cheung H., de Rooij B., Kroon J., et al. The BMP2/7 heterodimer inhibits the human breast cancer stem cell subpopulation and bone metastases formation. Oncogene 2011.